Cascade Prodrug Inc
We have a lead compound in preclinical trials which in tumor models shows significant improvement in safety and efficacy using the tumors own microenvironment
Cascade Prodrug Inc is in preclinical development of a novel drug utilizing it's proprietary technology platform. This compound is a prodrug derivative of blockbuster FDA approved agent to treat cancer. Data suggests this new form has the potential for significant improvement to the theraputic index of the parent. Our commercial strategy is to modify these parent drugs, create new prodrugs, then license/exit with a major pharmaceutical company.